Likewise, the combination therapy may not be recommended for patients with M2 along with a tumor size of 3–5cm, tumor number of two to three, or AFP >400 μg/L because adjuvant sorafenib seemed inadequate to enhance the efficacy of RFA. This evidence concerns the gene AFP and neoplasm.